Abbott has announced positive six-month data from its ABSORB trial, which showed its bioresorbable vascular scaffold (BVS) showed very low rates of adverse cardiac events (4.4%) and no blood clots (thromboses) when treating coronary artery disease.

The second stage of the ABSORB trial was conducted on 45 patients and showed an in-stent late loss rate of 0.19mm.

The device is made of polylactide, a proven biocompatible material that is commonly used in medical implants such as dissolving sutures.

Abbot beleieves the BVS technology has the potential to treat a blocked vessel like a metallic drug-eluting stent, without leaving a permanent implant behind after the vessel is healed.

The bioresorbable technology used in the device is designed to restore blood flow by opening a clogged vessel and providing support until it is healed.

Abbott’s BVS is under clinical investigation in Europe, Australia and New Zealand.